About US
Contact us
-
IPEC-Americas and IPEC Europe Publish Co-Processed Excipient GuideIPEC-Americas and IPEC Europe Publish Co-Processed Excipient GuideIPEC-Americas and IPEC Europe have jointly published the Co-processed Excipient Guide for excipient makers and users. The new guide of2017/11/8
-
Alkermes balks at U.S. senator’s probe into 'aggressive' Vivitrol lobbying and marketingA basketful of opioid makers have been drawn into federal and state investigations into their marketing practices, but now one U.S. senator is going after a company that says it’s just trying to help2017/11/8
-
Allergan executives named in investor suit over alleged generics price fixingShortly after taking a beating over its Restasis tribal patent maneuver, Allergan is facing allegations that it betrayed shareholder interests by colluding to fix prices with other generic companies2017/11/7
-
Higher compliance & better patient outcomes? See how.Finding the right patient services model isn’t a simple task. Traditionally, rare disease manufacturers have been served by multi-channel models made up of disparate service providers, each claiming2017/11/7
-
Roche job cuts mount to 365 as drugmaker rethinks packagingJust hours after Roche confirmed that 130 workers will be cut from a California facility by year-end, the drugmaker said it will shave 235 jobs from a plant in Europe as it switches up how it handles2017/11/6
-
Potential costs to AmerisourceBergen from DOJ probe pile up to $575MTalk is cheap until it involves negotiations to settle a federal probe. That is the experience of wholesaler AmerisourceBergen, which now sees costs to resolve federal investigations into its sales of2017/11/6
-
Sanofi falls short in Q3 as diabetes and MS sales disappointTo make up for a slow and painful decline of its aging diabetes unit, Sanofi has been counting on newer market entrieslike Aubagio and Lemtrada to treat multiple sclerosis. And during the third quarte2017/11/3
-
Teva cuts guidance yet again as Copaxone copies, generics pressure take their tollOn a day that Teva chairman Sol Barer described as “the beginning of the next chapter for our company,” all analysts got was more of the same. For the third time in the last four quarters, the comp2017/11/3
-
Insys takes $150M charge in Q3 as it works to settle Subsys probeRight on the heels of the high-profile arrest of Insys' billionaire founder John Kapoor, the drugmaker has recorded a $150 million charge as it works to put its Subsys legal problems in the past.2017/11/2
-
With pricing talk losing steam, lawmakers take on reducing costs due to wasted drugsCongress has failed to make progress on drug pricing reform, buta group of lawmakers are pushing for something they hope will be more agreeable: finding solutions to reduce drug waste, and so costs to2017/11/2